{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:49:52Z","timestamp":1791287392810,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","seizure-journal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.seizure.2023.04.009","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T15:28:41Z","timestamp":1680881321000},"page":"53-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Minimum effective sodium valproate dose in genetic generalized epilepsies"],"prefix":"10.1016","volume":"108","author":[{"given":"Vanessa Dinis","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Amorim","family":"Hackbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-8632","authenticated-orcid":false,"given":"Laura Maria","family":"Guilhoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeana Torres Corso","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Eduardo","family":"Peixoto-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elza M\u00e1rcia Targas","family":"Yacubian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian S.","family":"Bittar Guaranha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.seizure.2023.04.009_bib0001","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/epi.17236","article-title":"ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by ILAE Task Force on Nosology and Definitions","volume":"63","author":"Hirsch","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.04.009_bib0002","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for treatment of generalised and unclassifiable epilepsy: an unblinded randomized controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"10282","key":"10.1016\/j.seizure.2023.04.009_bib0003","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"SANAD II collaborators. The SANAD II study of effectiveness of valproate or levetiracetam in generalised and unclassifiable epilepsy: an un-blinded randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.seizure.2023.04.009_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/epi.12028","article-title":"Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2023.04.009_bib0005","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ene.13811","article-title":"Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors","volume":"26","author":"Stevelink","year":"2019","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2023.04.009_bib0006","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1038\/s41598-022-06324-2","article-title":"Sex-specific disease modifiers in juvenile myoclonic epilepsy","volume":"12","author":"Shakeshaft","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.seizure.2023.04.009_bib0007","unstructured":"European Medicines Agency. PRAC recommends strengthening the restrictions on the use of valproate in women and girls. Women to be better informed of the risks of valproate use during pregnancy. EMA\/612389\/2014. www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Valproate_and_related_substances_31\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500175214.pdf, Accessed date: 10 December 2019."},{"key":"10.1016\/j.seizure.2023.04.009_bib0008","series-title":"MHRA guide for healthcare professionals. information on the risks of valproate (epilim, depakote, convyulex, episenta, epival, kentlim, orlept, sodium valproate, syonell & valpal) use in girls (of any age) and women of childbearing potential","year":"2018"},{"key":"10.1016\/j.seizure.2023.04.009_bib0009","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.seizure.2023.04.009_bib0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"issue":"16","key":"10.1016\/j.seizure.2023.04.009_bib0011","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.seizure.2023.04.009_bib0012","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2023.04.009_bib0013","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1528-1157.1994.tb02432.x","article-title":"Juvenile myoclonic epilepsy: a 5-year prospective study","volume":"35","author":"Panayiotopoulus","year":"1994","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.seizure.2023.04.009_bib0014","first-page":"708","article-title":"Treatment of juvenile myoclonic epilepsy with low-dose sodium valproate","volume":"152","author":"De Toffol","year":"1996","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"10.1016\/j.seizure.2023.04.009_bib0015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s004150200028","article-title":"Low dose sodium valproate in the treatment of juvenile myoclonic epilepsy","volume":"249","author":"Karlovassitou-Koniari","year":"2002","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2023.04.009_bib0016","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/ane.12216","article-title":"Low-dose sodium valproate in the treatment of idiopathic generalized epilepsies","volume":"129","author":"Mir\u00f3","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2023.04.009_bib0017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.yebeh.2016.04.047","article-title":"High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: going from low to high","volume":"61","author":"Hern\u00e1ndez-Vanegas","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.04.009_bib0018","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2019.06.021","article-title":"Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy","volume":"70","author":"G\u00fcrer","year":"2019","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2023.04.009_bib0019","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/s-0040-1718853","article-title":"Experience with low-dose sodium valproate in idiopathic generalized epilepsy patients: a long-term follow-up study on selective cohort from North India","volume":"12","author":"Goel","year":"2021","journal-title":"J Neurosci Rural Pract"},{"key":"10.1016\/j.seizure.2023.04.009_bib0020","unstructured":"WHO (World Health Organization). Defined daily dose. Found at: https:\/\/www.whocc.no\/atc_ddd_index\/?code=N03AG01. Accessed in October 2022."},{"issue":"20","key":"10.1016\/j.seizure.2023.04.009_bib0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00007691-199804000-00004","article-title":"Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study","volume":"20","author":"Sundqvist","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2023.04.009_bib0022","doi-asserted-by":"crossref","unstructured":"Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389\u201399.","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"10.1016\/j.seizure.2023.04.009_bib0023","doi-asserted-by":"crossref","unstructured":"Hirsch E., French J., Scheffer I.E., Zuberi S.M., Trinka E., Specchio N., Somerville E., Samia P., Riney K., Nabbout R., Jain S., Bogacz A., Alsaadi T., Wilmshurst J.M., Auvin S., Wiebe S., Tinuper P., Wirrell E. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. 2022.","DOI":"10.1111\/epi.17236"},{"issue":"8","key":"10.1016\/j.seizure.2023.04.009_bib0024","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/archneur.60.8.1100","article-title":"Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy","volume":"60","author":"Prasad","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.seizure.2023.04.009_bib0025","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/01.wnl.0000313148.34629.1d","article-title":"Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy","volume":"70","author":"Baykan","year":"2008","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.seizure.2023.04.009_bib0026","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","article-title":"Effectiveness of first antiepileptic drug","volume":"42","author":"Kwan","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.04.009_bib0027","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.seizure.2020.06.011","article-title":"Adjunctive perampanel and myoclonic and absence seizures:post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy","volume":"80","author":"Brandt","year":"2020","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.seizure.2023.04.009_bib0028","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/epi.16821","article-title":"Perampanel and pregnancy","volume":"62","author":"Vazquez","year":"2021","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2023.04.009_bib0029","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/epi.13702","article-title":"Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies","volume":"58","author":"Gesche","year":"2017","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123001024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123001024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T12:52:08Z","timestamp":1714567928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":29,"alternative-id":["S1059131123001024"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.04.009","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimum effective sodium valproate dose in genetic generalized epilepsies","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}